There is wide interest in researching CTCs to identify means for improving cancer care and improving the targeting of new cancer drugs.
ANGLE is establishing collaborative partnerships with leading cancer research groups to ensure its Parsortix technology is widely adopted by the best in the field.
We will be considering joint development programmes with our partners, sharing skills, knowledge and resources where applicaple to achieve common goals.
The Paterson Institute for Cancer Research is a leading cancer research institute within The University of Manchester, core funded by Cancer Research UK, the largest independent cancer research organisation in the world.
Research within the Paterson Institute spans the whole spectrum of cancer research, from programmes investigating the molecular and cellular basis of cancer, to those focussed on translational research and the development of therapeutics. The Clinical and Experimental Pharmacology Group (CEP), was established in 2004, to fulfil the pressing medical need for bio-marker-focused translational research and is co-directed by Professor Caroline Dive and Professor Malcolm Ranson.
The CEP team was awarded the 2011 Cancer Research UK Prize for Translational Cancer Research. The prize recognises the work of researchers at the Cancer Research UK-funded Paterson Institute, The University of Manchester, Christie Hospital NHS Foundation Trust and AstraZeneca, who together have contributed to transforming the field of bio-marker research and early clinical trials. The team has had many successes in using bio-markers – substances that can be measured to determine several factors such as how well a patient is responding to a treatment – to enhance clinical trials and has been involved in over 70 clinical trials since 2004. The team’s accomplishments in translational research in lung cancer are an example of the many achievements that were recognised by the panel. They have discovered that circulating tumour cells (CTCs) in lung cancer patient blood can be used to predict response to treatment and thereby ensure better selection of treatment options for patients.
The group have leading expertise in prostate cancer and have developed a specialist model for culturing recovered cancer cells in the laboratory.
The oncology group at the Postgraduate Medical School, University of Surrey are a multidisciplinary team of cancer physicians and scientists who have an aim to develop, evaluate and deliver novel cancer therapies to patients. They have specialist expertise in urological and ovarian cancers, and conduct early phase trials across most cancer types.
The team is led by Prof Hardev Pandha, a clinician scientist and consultant in medical oncology, and Dr Richard Morgan, Senior lecturer in molecular oncology. In particular the group have the expertise and facilities to undertake human studies of targeted cancer therapies, cancer vaccines and oncolytic viral therapy. Clinical trials are conducted at St Luke’s Cancer Centre, in the neighbouring Royal Surrey County Hospital.
A particular strength of the group has been the emphasis on translational science associated with the trials. This includes the collection, archiving and evaluation of patient tissue and blood for biomarkers and discovery. The group currently numbers 24, has state-of-the-art laboratory facilities and scientific expertise to undertake new research projects with potential collaborators. The group has published 110 peer reviewed scientific papers since they moved to Surrey in 2006.